

Press release

Gothenburg, Sweden

January 28, 2019. 4.40 p.m. CET

CELLINK with partner has been granted project funding of SEK 10 million from the EU for the FUNC project. CELLINK's share amounts to SEK 5 million.

CELLINK, together with Academisch Centrum Tandheelkunde Amsterdam (ACTA), has been awarded funding for the project Functionalized Collagen-based Bioink for 3D Bioprinting – "FUNC."

The project will run for three years with a total budget of 19,5 MSEK. The project is financed to 50 percent through Eurostars. The consortium will develop a ready-to-use biofunctionalized collagen-based ink for 3D bioprinting. FUNC-BIOINK will provide mammalian (human) cells with an optimized biomimetic milieu. The incorporated peptides promote cell attachment, spreading and survival and direct differentiation. FUNC-BIOINK can be used to create a wide array of tissues. Due to its versatility and unmatched quality, FUNC-BIOINK is of interest to academia as well as cosmetic and pharmaceutical industries.

For further information, please contact:

Erik Gatenholm, CEO

Phone: EU +46 73 267 00 00

US +1 (650) 515 5566

Email: eg@cellink.com

Gusten Danielsson, CFO

Phone: +46 70 991 86 04

US +1 (857) 332 2138

Email: gd@cellink.com

About CELLINK

CELLINK is the leading 3D-bioprinter provider and the first bioink company in the world. We focus on developing and commercializing bioprinting technologies to allow researchers to print human organs and tissues for pharmaceutical and cosmetic applications. Founded in 2016 and active in more than 45 countries, CELLINK is changing the future of medicine as we know it. Visit www.cellink.com to learn more. CELLINK is listed on Nasdaq First North under CLNK. Erik Penser Bank AB is the company's certified adviser, available by phone at +46 846 383 00 and by email at: certifiedadviser@penser.se.